viewOpyl Ltd

Opyl non-executive director shows faith in company with on-market share purchase

Combining new technologies and healthcare expertise, Opyl’s key offerings include optimising clinical study design and recruitment strategies.

Opyl Ltd - Opyl non-executive director demonstrates faith in the company with on-market purchase of shares
Opyl is a new generation company working at the intersection of artificial intelligence, social media and clinical trials

Opyl Ltd (ASX:OPL) non-executive director Damon Rasheed has demonstrated his faith in the company’s vision to improve health and wellness by optimising data assets and digital activation with the purchase of shares in an on-market transaction.

Rasheed purchased 300,000 shares in a direct interest at 19.4 cents per share on September 8, increasing the total number of securities held after the change to 70,000 shares.

New software using AI 

The company has developed a software that uses artificial intelligence (AI) to make a probability of success prediction on the likelihood of a vaccine, drug, diagnostic or medical device succeeding in clinical trials.

Previous studies demonstrated that on average only 13.8% of all drugs in phase 1 clinical trials eventually win approval from regulators and enter the market.

Typically, vaccines have a higher success rate (33.4%) than most other drugs, while cancer drugs have a far lower rate of success (3%).

The application of the Opyl software platform is to work with drug and device development companies to refine their clinical trial approaches to improve the outcomes of their clinical studies, which reduces costs and accelerates the timeline to get new treatments to patients.

Quick facts: Opyl Ltd

Price: 0.19 AUD

Market: ASX
Market Cap: $7.01 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...


Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

on 9/12/19

2 min read